Profile: Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

34.02USD
11:00am EDT
Price Change (% chg)

$-0.09 (-0.26%)
Prev Close
$34.11
Open
$31.00
Day's High
$34.92
Day's Low
$30.75
Volume
130,911
Avg. Vol
116,882
52-wk High
$35.86
52-wk Low
$14.46

Search Stocks

Pacira Pharmaceuticals, Inc. (Pacira), formerly Pacira, Inc., incorporated in December 2006, is the holding company for the Company’s California operating subsidiary of the same name, which it refers to as PPI-California. The Company is a specialty pharmaceutical company focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its product candidate EXPAREL is a long-acting bupivacaine (anesthetic/analgesic) product for postsurgical pain management. EXPAREL provides analgesia for up to 72 hours post-surgery. EXPAREL consists of bupivacaine encapsulated in DepoFoam. DepoFoam, its extended release drug delivery technology, is the basis for its commercial products: DepoCyt(e) and DepoDur, which it manufactures for its commercial partners. Its product portfolio and product candidate pipeline include EXPAREL, DepoCyt, DepoDur, DepoNSAID and DepoMethotrexate.

EXPAREL

EXPAREL provides continuous and extended postsurgical analgesia for up to 72 hours and reduces the consumption of supplemental opioid medications. The safety of EXPAREL has been demonstrated in 21 clinical trials consisting of nine Phase-I trials, seven Phase-II trials and five Phase-III trials. Its pivotal Phase-III bunionectomy clinical trial was a multicenter, randomized, double-blind, placebo-controlled trial conducted in 193 patients at four sites in the United States. It has completed two Phase-II clinical trials, in which 40 patients received EXPAREL for nerve block.

DepoFoam

The Company’s product development activities utilize its DepoFoam drug delivery technology. DepoFoam consists of microscopic spherical particles composed of a honeycomb-like structure of numerous internal aqueous chambers containing an active drug ingredient. Each chamber is separated from adjacent chambers by lipid membranes. Following injection, the DepoFoam particles release drug over an extended period of time by erosion and/or reorganization of the particles’ lipid membranes. Release rates are determined by the choice and relative amounts of lipids in the formulation.

Depocyt(e)

DepoCyt(e) is a sustained-release liposomal formulation of the chemotherapeutic agent cytarabine utilizing the Company’s DepoFoam technology. Depocyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis, a complication of lymphoma. DepoCyt(e) is dosed once every two weeks in an outpatient setting.

DepoDur

DepoDur is an extended-release injectable formulation of morphine utilizing the Company’s DepoFoam technology. DepoDur is indicated for epidural administration for the treatment of pain following surgery. DepoDur provides effective pain relief of up to 48 hours and has demonstrated improved patient mobility and freedom from indwelling catheters.

DepoNSAID

The Company’s preclinical product candidates are extended release formulations of non-steroidal anti-inflammatory drugs (NSAIDs). It provides the benefits of injectable NSAIDs with a prolonged duration of action.

DepoMethotrexate

The Company’s preclinical product candidate, an extended release formulation of methotrexate, is designed to improve the market utility of methotrexate, a disease modifying anti-rheumatic drug. Methotrexate is the standard of care for therapy in rheumatoid arthritis, this agent is associated with nausea, vomiting and drowsiness due to blood levels immediately following traditional administration.

The Company competes with Durect Corporation and I-FLOW Corporation.

Company Address

Pacira Pharmaceuticals Inc

Suite 100, 5 Sylvan Way
PARSIPPANY   NJ   07054
P: +1973.2543560
F: +1302.6555049

Search Stocks